For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| General and administrative | 270,153 | 383,729 | 341,203 | 414,676* |
| Revenues | - | 0 | - | - |
| Research and development | 20,454 | 14,430 | 13,214 | 93,317.75* |
| Stock-based compensation | 277,226 | 250,189 | 231,933 | 1,849,987.25* |
| Total operating expenses | 567,833 | 648,348 | 586,350 | 2,357,981* |
| Interest expense, net | 958 | 1,070 | 909 | 960* |
| Net loss | -568,791 | -649,418 | -587,259 | -2,358,941 |
| Basic EPS | -0.03 | -0.034 | -0.03 | -0.131 |
| Diluted EPS | -0.03 | -0.034 | -0.03 | -0.131 |
| Basic Average Shares | 18,579,776 | 18,326,587 | 18,522,295 | 17,988,233 |
| Diluted Average Shares | 18,579,776 | 18,326,587 | 18,522,295 | 17,988,233 |
RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. (RTGN)